been recorded in the North of Scotland. However, there has been no prevalence study in this area since 1983.

**Aims** We undertook a new prevalence study of MS in Aberdeen City, and the Orkney and Shetland islands to: calculate age-gender specific prevalence rates; compare variations in age-gender standardised prevalence rates between areas and over time; calculate prevalence rates by MS sub-type, diagnostic criteria and to gather information on disability status.

**Methods** We used GP-practice records, hospital records and laboratory data for case ascertainment of patients alive and resident in the study area on prevalence day (24 September 2009), verified their diagnoses by reviewing medical records and included participants according to the research diagnostic criteria of Poser, McDonald 2001 and McDonald 2005. Information on disability was gathered from medical records and patient questionnaires. Prevalence rates and CIs were calculated assuming a Poisson distribution and standardised against the Scottish population (30 June 2009).

**Results** We found 590 patients in the combined study area (Aberdeen 442, Orkney 82, Shetland 66). Mean age was 52 years (SD ±15), and the age-standardised male to female ratio was 1.2 (95% CI 1.6 to 2.1). The standardised prevalence rate for the combined study area was 257 per 100 000 (95% CI 256 to 277), in Aberdeen City 257 per 100 000 (95% CI 214 to 257), in Orkney 421 per 100 000 (95% CI 329 to 512) and in Shetland 305 per 100 000 (95% CI 231 to 379). There were significant differences between Orkney and the other areas, and significant differences in the prevalence rates over time in Orkney and Shetland, but not for Aberdeen City. A relapse-remitting disease pattern was recorded in 50% of participants and 45% of patients had significant disability levels.

**Conclusion** The prevalence of MS has increased in the North of Scotland over the last 30 years, which may reflect methodological differences in studies over time, improved diagnostic methods, or a true increase in prevalence due to improved survival, higher incidence rates or as a result of migration. Currently Orkney has the highest MS prevalence rate in the world. New disability data could be used to plan health services in these communities.

**05-2.4** Low-grade systemic inflammation in early adolescence predicts suboptimal bone quality in late adolescence: a prospective study in the general population

doi:10.1136/jech.2011.142976b.46

**Introduction** Early inflammatory changes may explain the negative impact of adiposity on bone acquisition during childhood. We aimed at estimating the effect of systemic inflammation during adolescence on forearm bone mineral density at 17 years-old.

**Methods** We used data from 377 girls born in 1990 and assessed at 13 and 17 years-old (EFTTeen cohort). Adolescents were evaluated through physical examination, including height, weight and bone mineral density (BMD) at the forearm using dual-energy x-ray absorptiometry. Serum high-sensitivity C reactive protein (CRP) was quantified (participants over 10 mg/l were excluded). Associations between CRP and BMD were quantified using linear regression. Coefficients were adjusted for gynaecologic age, weight and height, to minimise confounding by body size.

**Results** Median (25th–75th percentiles) CRP concentration increased from 0.2 (0.1–0.5) mg/l at 13 to 0.6 (0.2–1.7) at 17 years-old. Mean (SD) BMD was 0.562 (0.085) g/cm² at 13 and 0.437 (0.052) g/cm² at 17. Adolescents in the upper quartile of CRP at 13 had similar adjusted mean BMD at that age but significantly lower BMD at 17 years-old when compared to those in the lowest quartile (–0.024, 95% CI −0.040 to −0.007). Additionally, girls in the two highest quartiles of CRP variation had significantly lower BMD at 17 when compared to the lowest quartile (–0.016, 95% CI −0.031 to −0.001 and –0.027, 95% CI −0.043 to −0.010, respectively).

**Conclusion** Systemic inflammation in early adolescence and its increase during follow-up, predicted lower bone quality in late adolescence, providing evidence that the negative association between obesity and bone accrual is probably mediated by low-grade inflammation.

**05-2.5** Life course BMI and risk of knee osteoarthritis at age 53: evidence from the 1946 British birth cohort study

doi:10.1136/jech.2011.142976b.47

**Introduction** We examined how body mass index (BMI) over the life-course influences the risk of later life knee osteoarthritis (OA), for example, whether knee OA risk accumulates with prolonged exposure to high BMI or whether later rather than earlier adult life is the key period of exposure.

**Methods** A population-based birth cohort study of 3035 men and women who underwent a clinical examination for knee OA at age 53. BMI was measured 10 times from 2 to 53 years. Analyses were stratified by gender and adjusted for occupation and activity levels.

**Results** The prevalence of knee OA was higher in women than men—12.9% (n=194) vs 7.4% (n=108). In men, the association between BMI and knee OA was apparent at age 20 (p=0.032) and remained until 53 yrs (OR per z-score: 1.38; 95% CI 1.11 to 1.71). In women, there was evidence for an association at 15 yrs (p=0.003); this became stronger through adulthood—at age 53 the OR was 1.89 (CI 1.59 to 2.24) per z-score increase in BMI. A structured modelling approach to disentangle the way in which BMI over life influenced knee OA risk suggested that in women, prolonged exposed to high BMI throughout adulthood carried the highest risk, while in men, it was exposure in mid adulthood that explained most of the risk.

**Conclusion** Our study suggests that, particularly in women, the duration of exposure to high BMI in adulthood is important in explaining knee OA risk, and that these associations originate from weight gain in childhood and adolescence.